Tumor Immunology Flashcards
tumor antigens
mutated protein normal cells do NOT express these antigens not available during neg. selection: loaded onto MHC class I and presented to CTLs
tumor-associated antigens
un-mutated protein that is encoded in germ-line DNA of a cell whose level of expression has been dramatically altered by a neoplastic event
1. embryonic cells not available in T cell development
MHC class I presents to T cells
2. increased expression of normal self protein
increased density can lead to recognition by effector CTLs
proto-oncogenes
when mutated and activated: transform normal cell into a tumor cell
tumor suppressor genes
gene that encodes a protein that exerts control on cell growth rates
oncogenic viruses
express antigens that can serve as tumor antigens
Adaptations of tumors that enable them to avoid immune detection or effector function
- down-regulation of MHC class I
2. down regulation of T cell activation or effector function: expression of CTLA-4, TGF-beta, Fas-ligand, or PDL-1
bispecific Ab
recombinant with two arms
1. specific for CD3
2. specific for tumor antigen
recruits CD8 T cells to tumor
NOT a specific antigen activation: any T cell can be recruited
close contact causes degranulation rather than MHC and B7
CAR
chimeric antigen receptor
CTL with B cell receptor (heavy, light, and CD3 zeta chain)
CD3 zeta chain: causes intracellular signaling ot occur
carcinoma
cancer of epithelial cells
sarcoma
cancer of CT or non epithelial cells
leukemia
cancer of circulating cells of immune system
lymphomas
cancer of immune system involving solid lymphoid tumors
myelomas
cancer of immune system involving bone marrow
What is the effector mechanism our immune system sometimes has against tumor cells?
CTL
syngenic tumor transplantation
can transfer tumor from one mouse to another if they have matching MHC haplotypes
proves CTL resonse
allogenic tumor transplantation
can NOT transfer tumor between mice with mismatching MHC haplotypes
proves CTL response
HER2
oncogene: GF receptor
breast cancer
B-RAF
oncogene: intracellular signal
melanoma
MYC
oncogene: TF
neuroblastoma
RAS
oncogene: intracellular signal
colorectal cancer
B-catenin
oncogene: intracellular signal
various cancers
VEGF
oncogene: angiogenesis
colorectal cancer
APC
tumor suppressor: scaffolding protein
colorectal cancer
TP53
tumor suppressor: regulates cell division
lung cancer
RB
tumor suppressor: regulates cell division
melanoma
CDKN2A
tumor suppressor: regulates cell division
melanoma
p53
tumor suppressor: regulates cell division
various cancers
MAGE, GAGE, BAGE, RAGE
target of CTL-mediated killing when expressed outside of testes (immunoprivileged: not available during T cell development)
oncofetal antigens
genes normally only expressed during embryonic development that are expressed in a tumor
NOT available for B and T cell negative selection
MUC-1
mucin found on many breast carcinomas
tumor specific carbohydrate and peptide epitopes: induces both antibody and T cell response
examples of abnormal forms or elevated levels of glycolipids and glycoproteins that can be diagnostic for cancers
gangliosides, blood group antigens, mucins
CA-125
mucin found in ovarian carcinomas
CA-19-9
mucin found in ovarian carcinomas
cell type specific differentiation antigens
normally expressed by a cell at different stages of differentiation of that cell type; tumor cell will typically express antigen that were being expressed by the cell when neoplastic event occurred
ex: CD20, CD1, CD3, CD4, CD8
normally recognized proteins that were available during thymic selection: no T cells specific for them
TGF-beta
immunosuppressive environment around the tumor
Fas-ligand
engage with Fas on immune cells and induce apoptosis
PD-L1
ligand for PD-1 on effector T cells
down regulation of function
protection from CTLs if expressed
How can tumors evade the immune system?
- defects in expression of MHC class I: Evade CTL but increase NK killing
- TGF-beta
- Fas-Ligand
- PD-L1
- CTLA-4
conjugated Ab
tumor-antigen specific MAb delivers toxin, drug or radio nucleotide to tumor
CTLA-4
on naive T cells and Tregs
binds B7, preventing CD28 from binding
causes T reg to secrete TGF-beta, preventing T cell activation
blinatumomab
biphasic Ab
anti-CD3 arm (T cell) and anti-C19 arm (tumor antigen)
Tx: B cell lymphoma